391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
J.A. Bridgewater(CRUK Lung Cancer Centre of Excellence), Juan W. Valle(Cancer Research UK Manchester Institute), Naureen Starling(Royal Marsden NHS Foundation Trust), David M. Wilson(AstraZeneca (Singapore)), H.S. Wasan(Imperial College Healthcare NHS Trust), Frank M.J.A. Froeling(Beatson West of Scotland Cancer Centre), M. Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), R. Hubner(The Christie NHS Foundation Trust), B. Markman(Monash Alfred Psychiatry Research centre), Louise Goodwin(Redx Pharma (United Kingdom)), Hilary H. Timmis(Redx Pharma (United Kingdom)), L. Chantrill, R. Gillmore(Royal Free London NHS Foundation Trust), Z. Setchellova(Redx Pharma (United Kingdom)), Caroline Phillips(Redx Pharma (United Kingdom)), Bishan Basu(University of Cambridge), Jane Robertson(Cancer Research UK), Frederick T. Collison(Leeds Teaching Hospitals NHS Trust), Simon A. Woodcock(Bio-Medical Science (South Korea))
Cited by 2
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k